

a

Primary tumor incidence in <i>Braf</i> ^{CA} , <i>Cdkn2a</i> ^{ff}	
$p = 0.0014$	
<i>Pten</i> ^{ff}	100% (53 of 53)
<i>Arf6</i> ^{Q67L}	80% (36 of 45)





b**e****c****d**

Figure S4. Primary tumor incidence, growth, survival and metastasis in *Pten*^{ff} vs. *Arf6*^{Q67L} mice.
(a) Increased tumor incidence (% = # of mice that developed a tumor / # TVA positive, injected mice) in *Pten*^{ff} vs. *Arf6*^{Q67L} cohorts. Fisher's exact test, two-tailed, $\alpha < 0.05$. (b) Primary tumor onset, unpaired t test with Welch's correction. (c) Primary tumor growth in *Pten*^{ff} vs. *Arf6*^{Q67L} mice upon tumor onset. Bars = SD. Two-way ANOVA, $\alpha=0.05$. (d) Overall survival upon tumor onset, log-rank (Mantel-Cox) test. (e) Comparison of spontaneous metastatic volume in each mouse cohort (see also schematic, Figure 1g). ANOVA ($p < 0.0001$) with Kruskal-Wallis multiple comparisons test (p values shown). ns=not significant. Identical data from the Control and *Arf6*^{Q67L} cohorts are also shown in Figure 1c with a slightly different Y axis spacing.